1. Impella 2.5® Device Is Associated with Improved Survival in AMICS
In the setting of acute myocardial infarction (AMI) cardiogenic shock (CS), Impella prior to percutaneous coronary intervention (PCI) has been associated with a survival benefit.
To assess outcomes of patients supported with Impella 2.5 prior to and after PCI on unprotected left main coronary artery (ULMCA) culprit lesion in AMICS.
This was a retrospective analysis of 36 consecutive patients in the cVAD Registry supported with Impella 2.5 for AMICS who underwent PCI on ULMCA culprit lesion.
Baseline characteristics were comparable between the pre- PCI group (n=20) and post-PCI group (n=16).
Non-ST segment elevation myocardial infarction and greater coronary disease burden were more frequent in the pre-PCI group, but this group had significantly better survival to discharge (55.0% vs 18.8%).
Kaplan Meier 30-day survival analysis showed poor survival in post-PCI group (48.1% vs 12.5%).
Impella 2.5 support before PCI on an ULMCA culprit lesion correlates with survival benefit in patients supported for AMICS.
Survival rates represent Kaplan-Meier estimates.
Kaplan-Meier analysis of survival through 30 days on the entire cohort (n=36) comparing the Pre-PCI group (n=20) and the Post-PCI group (n=16).
Kaplan-Meier analysis of survival through 30 days on patients who did not present with anoxic brain injury prior to Impella 2.5 support (n=25) comparing the Pre-PCI group (n=13) and the Post-PCI group (n=12). IM
Meraj PM et al. J Interv Cardiol